Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSDA group of diseases in which substances build up inside lysosomes because the body cannot break them down properly. Therapeutics to insist that an

This guidance is being distributed to all treating physicians worldwide except those in the European Union (EU). Separate guidance will

We would like to take this opportunity to provide an important update to the Pompe Community. Background In the early

We would like to take this opportunity to provide an important update to the global Pompe Community. Background In the

The US Food and Drug Administration (FDA) has informed Genzyme that the FDA plans an accelerated approval for alglucosidase alfa

The US Food and Drug Administration (FDA) held a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee on October

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced

We would like to take this opportunity to provide an important update related to Myozyme (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme.) manufacturing in the

In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in

CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme® (alglucosidase alfa)